AZD1222, a Coronavirus vaccine developed by Oxford University and AstraZeneca, a British pharmaceutical company, has successfully managed to trigger a strong immune response among older adults during the phase-II human trial.
According to the recently published results, the vaccine produced the desired immune response in adults aged 56 and above as they also experienced fewer side effects in comparison to younger individuals.
ALSO READ
Sindh Bans Testing of Asymptomatic Patients Under 60 Amid Shortage of Kits
With this, medical experts have raised hopes that this vaccine will offer protection to the high-risk age groups, who have disproportionately been affected during the COVID-19 pandemic.
Meanwhile, AstraZeneca is also conducting the phase-III clinical trial, whose results will be released in the next few weeks.
The Oxford vaccine will be made available first in the UK as the British government has already an agreement in place with Oxford University and AstraZeneca for 100 million doses of the effective variant of AZD1222.
ALSO READ
Apple Fined $113 Million for Intentionally Slowing Down iPhones
While the UK will be the first country to get access to AstraZeneca’s COVID-19 vaccine, the British government is also working to ensure that developing countries get the vaccine at the lowest possible cost, said Alok Sharma, UK’s Secretary of State for Business.
Besides, Pfizer/BioNTech, Russia, and Moderna have recently announced positive results from phase-III clinical trials of their Coronavirus vaccines.
